Core Insights - Celularity Inc. has filed its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025, regaining compliance with Nasdaq Listing Rule 5250(c)(1) [2][6] - The company has successfully retired all $32.0 million of senior secured debt along with $9.6 million in unpaid interest, which alleviates previous financial pressures [2][3] - Celularity is focusing on advancing its late-stage 510(k) pipeline products and exploring new opportunities in stem cell product sales [3] Financial Performance - The company faced challenges in the first half of 2025, including a significant secured debt overhang and uncertainties regarding wound care product reimbursement policies [3] - Despite these challenges, the company experienced substantial growth in wound care-related commercial product sales in the second half of 2024, which contributed to working capital pressures in early 2025 [3] Business Strategy - Celularity is restructuring its operations by establishing subsidiaries for each functional business unit to enhance operational efficiency [2] - The company aims to leverage traditional working capital facilities to support renewed sales growth in wound care products and advance its product pipeline [3] Company Overview - Celularity Inc. specializes in regenerative and cellular medicine, focusing on developing therapies derived from postpartum placenta to address age-related and degenerative diseases [4]